Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317625 | 0.89 | ADORA3 (0.53) | SMN1; SMN2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2315053 | 0.87 | RORC (0.49) | XIAPKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2315011 | 0.85 | ADORA2A (0.53) | XIAPKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2316516 | 0.81 | XIAP (0.57) | XIAPKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL27982784 | 0.78 | LMNA (0.45) | KDM4ESMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL2490939 | 0.77 | RORC (0.41) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2316563 | 0.77 | ALDH1A1 (0.54) | XIAPKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2754021 | 0.77 | XIAP (0.64) | XIAPKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL27711329 | 0.76 | SMN1; SMN2 (0.51) | KDM4ESMN1; SMN2ALDH1A1LMNAHPGD | |
| SCHEMBL3176221 | 0.75 | XIAP (0.66) | XIAPKDM4ESMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2380631-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2380631-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2349484-A2 | HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS | Novartis AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| CN-102119047-A | Heteroaryl derivatives as DGAT1 inhibitors | NOVARTIS AG | 2011-07-06 | — | — | CN | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007046-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | XIAP 3405/4885KDM4E 2341/4885SMN1; SMN2 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.